GSA Capital Partners LLP Has $647,000 Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

GSA Capital Partners LLP lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 19.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,101 shares of the company’s stock after selling 8,440 shares during the quarter. GSA Capital Partners LLP’s holdings in Hims & Hers Health were worth $647,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Versor Investments LP bought a new position in Hims & Hers Health during the 3rd quarter worth about $634,000. Los Angeles Capital Management LLC increased its holdings in Hims & Hers Health by 40.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company’s stock worth $743,000 after purchasing an additional 11,686 shares in the last quarter. State of New Jersey Common Pension Fund D increased its holdings in Hims & Hers Health by 30.1% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 123,587 shares of the company’s stock worth $2,276,000 after purchasing an additional 28,600 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Hims & Hers Health by 102.0% during the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after purchasing an additional 146,621 shares in the last quarter. Finally, Olympiad Research LP bought a new position in Hims & Hers Health during the 3rd quarter worth about $262,000. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research reports. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. TD Cowen lifted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.71.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,609 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the sale, the chief financial officer now owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. The trade was a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 996,961 shares of company stock worth $20,256,416 over the last three months. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 8.7 %

NYSE HIMS opened at $21.01 on Tuesday. Hims & Hers Health, Inc. has a 1-year low of $7.50 and a 1-year high of $30.44. The company has a market cap of $4.51 billion, a price-to-earnings ratio of 47.75 and a beta of 1.06. The company has a 50 day moving average of $19.90 and a 200-day moving average of $18.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The company’s revenue was up 77.1% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.